Cardiovascular Risk Reduction
Cardiovascular risk reduction covers steps taken to lower the chance of disease affecting the heart and blood vessels, often through lifestyle changes or medicines when needed.
Empagliflozin Tablets
10mg · 25mg
Empagliflozin tablets for type 2 diabetes and heart failure. They lower blood sugar by letting the kidneys remove it in urine.
Key points
- Cardiovascular disease is very common and is one of the main causes of death.
- For some people, the first sign may be chest pain, a heart attack, or a stroke, meaning the condition can appear without prior symptoms.
- Risk tends to be higher in people over 50, in men, and in those with a family history of cardiovascular disease.
Medicines listed for Cardiovascular Risk Reduction
The listed products contain telmisartan and empagliflozin, both supplied as tablets. Telmisartan is an angiotensin II receptor blocker that helps relax blood vessels and lower blood pressure, a key risk factor for cardiovascular disease. Empagliflozin is an SGLT2 inhibitor that works through the kidneys to reduce glucose reabsorption and has been studied for its cardiovascular effects. Both are listed here for their role in reducing risk to the heart and blood vessels.